Fortrea Holdings Inc. is a global contract research organization providing biopharmaceutical product and medical device development solutions. The company operates in a single reporting segment, Clinical Services, which encompasses Clinical Pharmacology, Clinical Development, and Consulting Services. Its Clinical Pharmacology division offers first-in-human studies, bioanalytics, and pharmacokinetics through clinical research units in the United Kingdom and the United States. Clinical Development provides phase I through IV trial management, regulatory affairs, data management, and medical writing, with a focus on therapeutic areas including oncology, central nervous system, metabolic disorders, and cell and gene therapies. The company serves pharmaceutical, biotechnology, and medical device customers across more than 20 therapeutic areas using Full Service, Functional Service Provider, and Hybrid delivery models. Fortrea was formed through the spin-off of the contract research organization business from Labcorp Holdings Inc. in 2023, following a history that includes the former name Covance and its acquisition by Labcorp. The company sells its Enabling Services segment, comprising Fortrea Patient Access Inc. and Endpoint Clinical, to an affiliate of Arsenal Capital Partners.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Diagnostics & Research Homepage fortrea.com
Sector Healthcare IR page ir.fortrea.com
Tags
clinical trial management, clinical pharmacology, biostatistics, pharmacovigilance, medical device development, cell and gene therapy, oncology, central nervous system, metabolic disorders, rare diseases, functional service provider, regulatory affairs, Fortrea Intelligent Technology, FortreaRx, Fortrea Patient Access Inc., Endpoint Clinical, Covance, Labcorp Drug Development, RCRI, Chiltern
Press page —

Metrics

Valuation  
Market cap $ 1.925B
Market cap (USD) $ 1.925B
P/E -31.67
PEG —
P/BV 3.62
P/S 0.72
P/OCF 9.54
P/FCF 11.39
Dividend yield —
Turnover / mcap —
Returns  
ROE -102.4%
ROI -61.0%
ROIC -40.5%
Profit margin -36.2%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 198.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 21
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 2.723B 2.696B 3.109B 2.837B 3.058B
Net profit -986.2M -328.5M -3.4M 186.2M 98M
Free cash flow 88.3M 237.3M 127.1M 28.3M 143.3M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 17.25 18.65 34.9 — —
Price performance 12m -0.08 -0.47 — — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — 0.00 26.1M 74.8M 4.8M
Borrowings, non-current (USD) — — 0.00 1.57B 1.05B 1.05B
Lease liabilities (USD) — — 63.4M 86M 74M 63.2M
Cash and deposits (USD) 80.3M 94.6M 112M 109M 119M 175M
Intangible assets (USD) — — 823M 771M 656M 622M
Right-of-use assets (USD) — — 50M 78.2M 66.2M 56M
Net debt (borrowings + leases - cash) (USD) — — -48.6M 1.57B 1.08B 941M
Cash flow detail
Operating cash flow (USD) — 170M 87.5M 167M 263M 114M
Purchases of property, plant and equipment (USD) — -26.5M -54.4M -40.3M -25.5M -25.2M
Change in payables (cash effect) (USD) — -6.2M 22.4M 51.1M 7.2M -110M
Interest paid (cash effect) (USD) — -200,000 -400,000 -45.1M -110M -91.2M
Income taxes paid (cash effect) (USD) — -16.1M -27M -18M -53.7M -16.9M
Share-based compensation (USD) — 27.5M 25.4M 42.7M 58.4M 74.4M
Free cash flow (OCF - PPE - intangibles) (USD) — 143M 33.1M 127M 237M 88.3M
Income detail
Total comprehensive income (USD) — 70M 65.3M 54.2M -396M -873M
Comprehensive income to owners (USD) — 70M 65.3M 54.2M -396M -873M
Provision for credit losses (USD) — — 3.4M 27.8M 22.2M 12M
Reported Mar 13, 2024 Mar 13, 2024 Mar 13, 2024 Mar 13, 2024 Mar 3, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Fortrea Reports Third Quarter 2026 Results Bull 4 Bear 0 Results

29 October 2026

PDF Version

Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundation

Highlights

For the three months ended September 30, 2026:

  • Revenues of $691.5 million

  • Book-to-bill ratio of 1.12x, resulting in 1.12x book-to-bill for the trailing 12 months

  • GAAP net income of $0.6 million, or $0.01 per diluted share

  • Adjusted EBITDA of $58.0 million

  • Adjusted net income of $27.9 million, or $0.28 per diluted share

  • Cash provided by operations of $60.8 million and free cash flow of $52.5 million

  • Raised midpoints of full-year revenue and adjusted EBITDA guidance and narrowed ranges

DURHAM, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today reported financial results for the third quarter ended September 30, 2026.

“Fortrea delivered another quarter of progress on our return-to-growth strategy, reflecting stronger commercial execution, continued operational improvements and financial discipline,” said Anshul Thakral, CEO of Fortrea. “Our sustained bookings momentum is building a foundation for growth, while targeted investments in early clinical development and technology enhance our ability to deliver differentiated value to clients. I’m proud of how Fortrea’s teams around the world are embracing our future direction while delivering for clients today. Our continued execution against our priorities gives us confidence to raise the midpoints of full-year guidance while narrowing ranges. We remain focused on translating stronger demand into revenue growth, margin expansion and long-term shareholder value.”

Third Quarter 2026 Financial Results

Revenue for the third quarter was $691.5 million, compared to $701.3 million in the third quarter of 2025.

Third quarter GAAP net income was $0.6 million and diluted income per share was $0.01, compared to third quarter of 2025 GAAP net loss of $(15.9) million and diluted loss per share of $(0.17). Third quarter adjusted net income was $27.9 million and adjusted diluted EPS was $0.28, compared to third quarter of 2025 adjusted net income of $11.7 million and adjusted diluted EPS of $0.12. Third quarter adjusted EBITDA was $58.0 million, compared to third quarter of 2025 adjusted EBITDA of $50.7 million.

During the third quarter, the Company performed a detailed review of contracts included in its backlog. As a result, the Company reduced backlog by $558 million to reflect the cumulative impact of estimated scope and study delivery requirements across customer contracts, including inactive trials. The adjustment has no impact on historical financial results, previously issued or current 2026 guidance, or near-term revenue estimates. As adjusted, backlog as of September 30, 2026, was $7,316 million. The book-to-bill ratio, which was not impacted by the adjustment, was 1.12x for the quarter.

Year-to-Date 2026 Financial Results

Year-to-date revenue was $2,006.2 million, compared to $2,062.9 million in the same period of 2025.

Year-to-date GAAP net loss was $(36.2) million and diluted loss per share was $(0.38), compared to net loss of $(953.7) million and diluted loss per share of $(10.53), inclusive of a non-cash goodwill impairment charge of $797.9 million, for the same period of 2025. Year-to-date adjusted net income was $65.8 million and adjusted diluted EPS was $0.66, compared to adjusted net income of $31.2 million and adjusted diluted EPS of $0.34 for the same period of 2025. Year-to-date adjusted EBITDA was $163.7 million, compared to adjusted EBITDA of $135.9 million for the same period of 2025.

2026 Financial Guidance

The Company updated its full-year 2026 guidance, narrowing the revenue and adjusted EBITDA ranges and raising both midpoints. The Company now expects revenues of $2,665 million to $2,690 million and adjusted EBITDA of $210 million to $218 million.

Earnings Call and Replay

Fortrea will host a conference call at 8:00 am ET on October 29, 2026, to review its third quarter financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast link. A replay of the live conference call will be available shortly after the conclusion of the event and accessible on the events and presentations section of the Fortrea website. A supplemental slide presentation will also be available on the Investor Relations website prior to the start of the call.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services, delivered in highly flexible models that include full service, functional service provider and hybrid service structures. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, technology innovation and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, the Company’s 2026 financial guidance. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “guidance,” “expect,” “assume,” “anticipate,” “intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements, including the Company’s 2026 financial guidance, are not guarantees of future performance and are subject to known and unknown risks and uncertainties, many of which are beyond the Company’s control. Actual results may differ materially from the Company’s expectations due to a number of factors, including, but not limited to, the following: the Company’s dependence on third parties generally to provide services critical to its businesses; the Company’s ability to successfully implement the Company’s business strategies and execute the Company’s long-term value creation strategy; risks and expenses associated with the Company’s international operations, tariff policies, trade sanctions and other trade restrictions and currency fluctuations; the anticipated benefits of the Company’s acquisition of the Early Phase Services division of Worldwide Clinical Trials; the Company’s customer or therapeutic area concentrations; the Company’s adoption and use of technology within its business and the risks that the Company may not be able to capture the anticipated benefits of such technology or that such technology may have negative effects; the outcome and impact of pending or future litigation; any further deterioration in the macroeconomic environment, particularly within the pharmaceutical and biotechnology industry, or further changes in government regulations and funding, which could lead to defaults or cancellations by the Company’s customers; the risk that the Company’s backlog and net new business may not grow to the extent anticipated over a specified period of time or be indicative of the Company’s future revenues and that the Company might not realize all of the anticipated future revenue reflected in the Company’s backlog; the Company’s ability to generate sufficient net new business awards, or if net new business awards are delayed, terminated, reduced in scope, or fail to go to contract; if the Company underprices its contracts, overruns its cost estimates, or fails to receive approval for, or experiences delays in documentation of change orders; and other factors described from time to time in documents that the Company files with the Securities and Exchange Commission (the “SEC”). For a further discussion of the risks relating to the Company’s business, see the “Risk Factors” Section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC, as such factors may be amended or updated from time to time in the Company’s subsequent periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in the Company’s filings with the SEC. Comparisons of results for current and any prior periods are not intended to express any future trends, or indications of future performance, unless expressed as such, and should only be viewed as historical data. All forward-looking statements are made only as of the date of this release and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments.

Note on Non-GAAP Financial Measures

This release includes information based on financial measures that are not recognized under generally accepted accounting principles in the United States ("GAAP"), such as Adjusted EBITDA, Adjusted Net Income, Adjusted Basic and Diluted EPS, and Free Cash Flow. Non-GAAP financial measures are presented only as a supplement to the Company’s financial statements based on GAAP. Non-GAAP financial information is provided to enhance understanding of the Company’s financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP, and non-GAAP measures should not be considered in isolation from, or as a substitute analysis for, the Company’s results of operations as determined in accordance with GAAP.

The Company uses non-GAAP measures in its operational and financial decision making and believes that it is useful to exclude certain items in order to focus on what it regards to be a more meaningful indicator of the underlying operating performance of the business. For example, in calculating Adjusted EBITDA, the Company excludes all the amortization of intangible assets associated with acquired customer relationships and backlog, databases, non-compete agreements and trademarks, trade names and other from non-GAAP expense and income measures, as such amounts can be significantly impacted by the timing and size of acquisitions. Although the Company excludes amortization of acquired intangible assets from the Company’s non-GAAP expenses, the Company believes that it is important for investors to understand that revenue generated from such intangibles is included within revenue in determining net income attributable to the Company. Internal management reports feature non-GAAP measures which are also used to prepare strategic plans and annual budgets and review management compensation. The Company also believes that investors may find non-GAAP financial measures useful for the same reasons, although investors are cautioned that non-GAAP financial measures are not a substitute for GAAP disclosures.

The non-GAAP financial measures are not presented in accordance with GAAP. Please refer to the schedules attached to this release for relevant definitions and reconciliations of non-GAAP financial measures contained herein to the most directly comparable GAAP measures. The Company’s full-year 2026 guidance measures (other than revenue) are provided on a non-GAAP basis without a reconciliation to the most directly comparable GAAP measure because the Company is unable to predict with a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable efforts. Such items include, but are not limited to, acquisition-related expenses, restructuring and related expenses, goodwill impairment, stock-based compensation and other items not reflective of the Company's ongoing operations.

Non-GAAP measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to the Company, many of which present non-GAAP measures when reporting their results. Non-GAAP measures have limitations as an analytical tool. They are not presentations made in accordance with GAAP, are not measures of financial condition or liquidity and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Non-GAAP measures are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider such performance measures in isolation from, or as a substitute analysis for, the Company’s results of operations as determined in accordance with GAAP.

Fortrea Contacts

Tracy Krumme (Investors) – 984-385-6707, [email protected] Sue Zaranek (Media) – 919-943-5422, [email protected] Kate Dillon (Media) – 646-818-9115, [email protected]

| | | | |

| FORTREA HOLDINGS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data) (unaudited) |

| | | | |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| Revenues | $ | 691.5 | | | $ | 701.3 | | | $ | 2,006.2 | | | $ | 2,062.9 | |

| Costs and expenses: | | | | | | | |

| Direct costs, exclusive of depreciation and amortization | | 552.0 | | | | 578.6 | | | | 1,603.9 | | | | 1,690.2 | |

| Selling, general and administrative expenses, exclusive of depreciation and amortization | | 103.8 | | | | 106.8 | | | | 306.4 | | | | 353.4 | |

| Depreciation and amortization | | 20.0 | | | | 19.6 | | | | 59.4 | | | | 58.7 | |

| Goodwill and other asset impairments | | — | | | | — | | | | — | | | | 797.9 | |

| Restructuring and other charges | | 0.7 | | | | 4.9 | | | | 10.1 | | | | 21.7 | |

| Total costs and expenses | | 676.5 | | | | 709.9 | | | | 1,979.8 | | | | 2,921.9 | |

| Operating income (loss) | | 15.0 | | | | (8.6 | ) | | | 26.4 | | | | (859.0 | ) |

| Other income (expense): | | | | | | | |

| Interest expense | | (20.2 | ) | | | (22.6 | ) | | | (58.6 | ) | | | (68.2 | ) |

| Foreign exchange gain (loss) | | 1.3 | | | | (2.6 | ) | | | 14.5 | | | | (28.1 | ) |

| Other, net | | 0.3 | | | | 5.1 | | | | 0.6 | | | | 7.9 | |

| Loss before income taxes | | (3.6 | ) | | | (28.7 | ) | | | (17.1 | ) | | | (947.4 | ) |

| Income tax (benefit) expense | | (4.2 | ) | | | (12.8 | ) | | | 19.1 | | | | 6.3 | |

| Net income (loss) | $ | 0.6 | | | $ | (15.9 | ) | | $ | (36.2 | ) | | $ | (953.7 | ) |

| | | | | | | | |

| Earnings (loss) per common share | | | | | | | |

| Basic and diluted | $ | 0.01 | | | $ | (0.17 | ) | | $ | (0.38 | ) | | $ | (10.53 | ) |

| | | | | | | | | | | | | | | | |

| FORTREA HOLDINGS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (dollars and shares in millions) (unaudited) |

| | | | |

| | September 30, 2026 | | December 31, 2025 |

| ASSETS | | | |

| Current assets: | | | |

| Cash and cash equivalents | $ | 220.6 | | | $ | 174.6 | |

| Accounts receivable and unbilled services, net | | 641.1 | | | | 589.7 | |

| Prepaid expenses and other | | 91.0 | | | | 132.9 | |

| Total current assets | | 952.7 | | | | 897.2 | |

| Property, plant and equipment, net | | 158.6 | | | | 149.5 | |

| Goodwill, net | | 949.9 | | | | 960.0 | |

| Intangible assets, net | | 572.0 | | | | 622.0 | |

| Deferred income taxes | | 6.2 | | | | 6.2 | |

| Other assets, net | | 98.8 | | | | 80.8 | |

| Total assets | $ | 2,738.2 | | | $ | 2,715.7 | |

| LIABILITIES AND EQUITY | | | |

| Current liabilities: | | | |

| Accounts payable | $ | 53.0 | | | $ | 29.7 | |

| Accrued expenses and other current liabilities | | 372.1 | | | | 395.8 | |

| Unearned revenue | | 525.5 | | | | 473.8 | |

| Current portion of long-term debt | | 23.4 | | | | 4.8 | |

| Short-term operating lease liabilities | | 9.3 | | | | 9.2 | |

| Total current liabilities | | 983.3 | | | | 913.3 | |

| Long-term debt, less current portion | | 1,031.9 | | | | 1,048.0 | |

| Operating lease liabilities | | 53.8 | | | | 54.0 | |

| Deferred income taxes and other tax liabilities | | 97.1 | | | | 97.6 | |

| Other liabilities | | 39.8 | | | | 39.3 | |

| Total liabilities | | 2,205.9 | | | | 2,152.2 | |

| Commitments and contingent liabilities | | | |

| Equity: | | | |

| Common stock, 96.5 and 93.1 shares outstanding at September 30, 2026 and December 31, 2025, respectively | | 0.1 | | | | 0.1 | |

| Additional paid-in capital | | 2,152.6 | | | | 2,116.6 | |

| Accumulated deficit | | (1,419.4 | ) | | | (1,383.2 | ) |

| Accumulated other comprehensive loss | | (201.0 | ) | | | (170.0 | ) |

| Total equity | | 532.3 | | | | 563.5 | |

| Total liabilities and equity | $ | 2,738.2 | | | $ | 2,715.7 | |

| | | | | | | | |

| FORTREA HOLDINGS INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions) (unaudited) |

| | |

| | Nine Months Ended September 30, |

| | 2026 | | 2025 |

| CASH FLOWS FROM OPERATING ACTIVITIES: | | | |

| Net loss | $ | (36.2 | ) | | $ | (953.7 | ) |

| Adjustments to reconcile net loss to net cash provided by (used for) operating activities: | | | |

| Depreciation and amortization | | 59.4 | | | | 58.7 | |

| Stock compensation | | 36.0 | | | | 59.6 | |

| Credit loss expense | | 4.0 | | | | 13.5 | |

| Operating lease right-of-use asset expense | | 6.2 | | | | 8.6 | |

| Operating lease right-of-use asset impairment | | — | | | | 1.3 | |

| Goodwill and other asset impairments | | — | | | | 797.9 | |

| Deferred income taxes | | 1.0 | | | | (24.4 | ) |

| Unrealized foreign exchange movements | | (13.2 | ) | | | 38.8 | |

| Other, net | | 2.8 | | | | 2.2 | |

| Changes in assets and liabilities: | | | |

| Increase in accounts receivable and unbilled services, net | | (55.3 | ) | | | (10.6 | ) |

| Decrease in prepaid expenses and other | | 20.3 | | | | 43.8 | |

| Increase (decrease) in accounts payable | | 23.7 | | | | (89.7 | ) |

| Increase in unearned revenue | | 51.0 | | | | 54.6 | |

| Decrease in accrued expenses and other | | (27.0 | ) | | | (16.2 | ) |

| Net cash provided by (used for) operating activities | | 72.7 | | | | (15.6 | ) |

| CASH FLOWS FROM INVESTING ACTIVITIES: | | | |

| Capital expenditures | | (25.3 | ) | | | (17.7 | ) |

| Proceeds from sale of business, net | | — | | | | 39.6 | |

| Proceeds from sale of assets | | 2.0 | | | | — | |

| Net cash (used for) provided by investing activities | | (23.3 | ) | | | 21.9 | |

| CASH FLOWS FROM FINANCING ACTIVITIES: | | | |

| Proceeds from revolving credit facilities | | — | | | | 453.9 | |

| Payments on revolving credit facilities | | — | | | | (453.9 | ) |

| Debt issuance costs | | — | | | | (0.6 | ) |

| Net cash used for financing activities | | — | | | | (0.6 | ) |

| Effect of exchange rate changes on cash and cash equivalents | | (3.4 | ) | | | 7.1 | |

| Net change in cash and cash equivalents | | 46.0 | | | | 12.8 | |

| Cash and cash equivalents at beginning of period | | 174.6 | | | | 118.5 | |

| Cash and cash equivalents at end of period | $ | 220.6 | | | $ | 131.3 | |

| | | | | | | | |

| RECONCILIATION OF NON-GAAP MEASURES FORTREA HOLDINGS INC. NET INCOME TO ADJUSTED EBITDA RECONCILIATION (in millions) (unaudited) |

| | | | | | |

| | Trailing Twelve Months Ended | | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | September 30, 2026 | | 2026 | | 2025 | | 2026 | | 2025 |

| Adjusted EBITDA: | | | | | | | | | |

| Net income (loss) | $ | (68.7 | ) | | $ | 0.6 | | | $ | (15.9 | ) | | $ | (36.2 | ) | | $ | (953.7 | ) |

| Income tax expense (benefit) | | 16.0 | | | | (4.2 | ) | | | (12.8 | ) | | | 19.1 | | | | 6.3 | |

| Interest expense | | 81.8 | | | | 20.2 | | | | 22.6 | | | | 58.6 | | | | 68.2 | |

| Foreign exchange (gain) loss | | (15.7 | ) | | | (1.3 | ) | | | 2.6 | | | | (14.5 | ) | | | 28.1 | |

| Depreciation and amortization (a) | | 78.7 | | | | 20.0 | | | | 19.6 | | | | 59.4 | | | | 58.7 | |

| Goodwill and other asset impairments | | — | | | | — | | | | — | | | | — | | | | 797.9 | |

| Restructuring and other charges (b) | | 38.0 | | | | 1.4 | | | | 6.3 | | | | 12.7 | | | | 23.8 | |

| Stock based compensation | | 50.8 | | | | 12.0 | | | | 22.3 | | | | 36.0 | | | | 59.6 | |

| Acquisition and disposition-related costs (c) | | 3.9 | | | | 2.8 | | | | 2.3 | | | | 2.8 | | | | 8.9 | |

| One-time spin-related costs (d) | | 2.3 | | | | — | | | | 3.0 | | | | 1.0 | | | | 23.4 | |

| CEO transition related costs | | — | | | | — | | | | 0.3 | | | | — | | | | 5.1 | |

| Receivables securitization yield expense | | 17.3 | | | | 4.2 | | | | 4.5 | | | | 13.0 | | | | 13.4 | |

| Cloud computing arrangements (e) | | 4.6 | | | | 1.2 | | | | 0.9 | | | | 3.6 | | | | 2.1 | |

| Other (f) | | 8.7 | | | | 1.1 | | | | (5.0 | ) | | | 8.2 | | | | (5.9 | ) |

| Adjusted EBITDA | $ | 217.7 | | | $ | 58.0 | | | $ | 50.7 | | | $ | 163.7 | | | $ | 135.9 | |

| | | | | | | | | | | | | | | | | | | | |

(a) Includes amortization of intangible assets acquired as part of business acquisitions.

(b) Restructuring and other charges represent amounts incurred in connection with the elimination of redundant positions, organizational realignment initiatives, and other actions taken to reduce overcapacity, align resources and facilities, and restructure certain operations.

(c) Acquisition-related costs include transaction, integration, and other direct and incremental costs incurred in connection with acquisitions. Disposition-related costs are short-term incremental costs to support the transition services agreement associated with the sale of the Enabling Services Segment.

(d) Represents one-time or incremental costs required to implement capabilities to exit the transition services agreement with the Company’s former parent.

(e) Represents amortization of implementation costs deferred in connection with cloud computing arrangements.

(f) Includes adjustments to estimated contingent consideration on a sale of a facility, income related to services provided under transition services agreements, certain legal expenses related to specifically identified litigation matters, including the shareholder litigation and the CFO transition-related litigation, settlements related to litigation initiated prior to the spinoff of the Company as a standalone company, and non-recurring business advisory consulting services.

| | | | |

| FORTREA HOLDINGS INC. NET INCOME TO ADJUSTED NET INCOME RECONCILIATION (in millions, except per share data) (unaudited) |

| | | | |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | 2026 | | 2025 | | 2026 | | 2025 |

| Adjusted net income: | | | | | | | |

| Net income (loss) | $ | 0.6 | | | $ | (15.9 | ) | | $ | (36.2 | ) | | $ | (953.7 | ) |

| Foreign exchange (gain) loss | | (1.3 | ) | | | 2.6 | | | | (14.5 | ) | | | 28.1 | |

| Amortization (a) | | 14.5 | | | | 14.8 | | | | 43.7 | | | | 43.9 | |

| Goodwill and other asset impairments | | — | | | | — | | | | — | | | | 797.9 | |

| Restructuring and other charges (b) | | 1.4 | | | | 6.3 | | | | 12.7 | | | | 23.8 | |

| Stock based compensation | | 12.0 | | | | 22.3 | | | | 36.0 | | | | 59.6 | |

| Acquisition and disposition-related costs (c) | | 2.8 | | | | 2.3 | | | | 2.8 | | | | 8.9 | |

| One-time spin-related costs (d) | | — | | | | 3.0 | | | | 1.0 | | | | 23.4 | |

| CEO transition related costs | | — | | | | 0.3 | | | | — | | | | 5.1 | |

| Receivables securitization yield expense | | 4.2 | | | | 4.5 | | | | 13.0 | | | | 13.4 | |

| Cloud computing arrangements (e) | | 1.2 | | | | 0.9 | | | | 3.6 | | | | 2.1 | |

| Other (f) | | 1.1 | | | | (5.0 | ) | | | 8.2 | | | | (5.9 | ) |

| Income tax impact of adjustments (g) | | (8.6 | ) | | | (24.4 | ) | | | (4.5 | ) | | | (15.4 | ) |

| Adjusted net income | $ | 27.9 | | | $ | 11.7 | | | $ | 65.8 | | | $ | 31.2 | |

| | | | | | | | |

| Basic shares | | 95.6 | | | | 91.2 | | | | 94.6 | | | | 90.6 | |

| Diluted shares | | 101.2 | | | | 93.8 | | | | 99.6 | | | | 92.0 | |

| Adjusted basic EPS | $ | 0.29 | | | $ | 0.13 | | | $ | 0.70 | | | $ | 0.34 | |

| Adjusted diluted EPS | $ | 0.28 | | | $ | 0.12 | | | $ | 0.66 | | | $ | 0.34 | |

| | | | | | | | | | | | | | | | |

(a) Includes amortization of intangible assets acquired as part of business acquisitions.

(b) Restructuring and other charges represent amounts incurred in connection with the elimination of redundant positions, organizational realignment initiatives, and other actions taken to reduce overcapacity, align resources and facilities, and restructure certain operations.

(c) Acquisition-related costs include transaction, integration, and other direct and incremental costs incurred in connection with acquisitions. Disposition-related costs are short-term incremental costs to support the transition services agreement associated with the sale of the Enabling Services Segment.

(d) Represents one-time or incremental costs required to implement capabilities to exit the transition services agreement with the Company’s former parent.

(e) Represents amortization of implementation costs deferred in connection with cloud computing arrangements.

(f) Includes adjustments to estimated contingent consideration on a sale of a facility, income related to services provided under transition services agreements, certain legal expenses related to specifically identified litigation matters, including the shareholder litigation and the CFO transition-related litigation, settlements related to litigation initiated prior to the spinoff of the Company as a standalone company, and non-recurring business advisory consulting services.

(g) Income tax impact of adjustments represents the amount of additional tax expense that the Company estimates it would record if it used Non-GAAP results instead of GAAP results in the calculation of its provision.

| | | | |

| FORTREA HOLDINGS INC. NET CASH PROVIDED BY OPERATING ACTIVITIES TO FREE CASH FLOW RECONCILIATION (in millions) (unaudited) |

| | | | |

| | Three Months Ended September 30, 2026 | | Nine Months Ended September 30, 2026 |

| Net cash provided by operating activities | $ | 60.8 | | | $ | 72.7 | |

| Capital expenditures | | (8.3 | ) | | | (25.3 | ) |

| Free cash flow | $ | 52.5 | | | $ | 47.4 | |

| | | | | | | | |

Fortrea Logo

Opt-Out Request Honored

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer. For more information, please see our Website Privacy Policy.

Allow All Cookies

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Cookies Details

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Cookies Details

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Cookies Details

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookies Details

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All Non-Essential Cookies

Powered by Onetrust

27 October 2026

PDF Version

DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations Tracy Krumme will participate in the following conference:

Jefferies Global Healthcare Conference (London, U.K.) **Date:**Tuesday, November 17, 2026 Format: Fireside Chat & 1x1 and Group Meetings **Time:**8:30 AM – 8:55 AM EST | 1:30 PM – 1:55 PM GMT Webcast:FTRE Jefferies Webcast

The live webcast and video replay of the Jefferies fireside chat will be accessible through the “Events” section of Fortrea’s Investor Relations website. Investors interested in meeting with management should contact their banking representatives.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.

Fortrea Contacts

Tracy Krumme (Investors) – 984-385-6707, [email protected] Sue Zaranek (Media) – 919-943-5422, [email protected] Kate Dillon (Media) – 646-818-9115, [email protected]

Fortrea Logo

Opt-Out Request Honored

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer. For more information, please see our Website Privacy Policy.

Allow All Cookies

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Cookies Details

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Cookies Details

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Cookies Details

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookies Details

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All Non-Essential Cookies

Powered by Onetrust

22 October 2026

PDF Version

Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia

Highlights

  • Collaboration aims to accelerate precision oncology research in Australia

  • Combines Fortrea’s experience in oncology clinical trials with Omico’s Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program

  • Together, Fortrea and Omico offer more efficient investigator site selection and faster patient access by connecting patients with relevant biomarker-driven clinical trials

DURHAM, N.C. and SYDNEY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), and Omico, Australia’s leading precision oncology screening and trial matching organization, today announced a collaboration to accelerate precision oncology research by helping connect cancer patients to biomarker-matched clinical trials. By combining Omico's precision oncology network with Fortrea's scientific and clinical trial experience, the joint effort aims to improve study planning, site selection and patient recruitment to expand access to biomarker-driven oncology research globally.

Through this initiative, Omico will support Fortrea’s clients in their oncology drug development needs by providing access to patient population insights, including genomic profiling, trial-matching capabilities, real-world oncology data and patient referral pathways in Australia, a key country both for early and late phase Oncology clinical research activities. The collaboration will combine Fortrea’s oncology drug development experience with Omico’s flagship Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program, the largest cancer genomics initiative in Australia. PrOSPeCT is designed to provide molecular profiling and help match patients to biomarker-driven clinical trials and targeted therapies.

“Our collaboration with Omico is about seeking to reach the right patient for the right study as quickly as possible,” said Oren Cohen, M.D., Chief Medical Officer at Fortrea. “Modern oncology development demands ever-greater precision to match specific cancers with the therapies most likely to benefit patients, and to do so as quickly as possible. Our work with Omico accelerates our ability to identify the right patients for biomarker-driven studies in Australia and help advance precision medicine for people with cancer.”

Omico has built one of Australia's most extensive precision oncology ecosystems, combining molecular profiling, real-world evidence, cohort research programs and a nationwide network of investigators and clinical sites. Omico has reported more than 23,000 consented patients within its clinic-genomic databases and has received referrals from more than 1,600 clinicians across Australia.

“Australia is well positioned to support global biomarker-driven clinical trials, through Omico’s established national precision oncology research infrastructure, expertise and networks,” said Professor David Thomas, Chief Science and Strategy Officer at Omico. “By combining our national data and trial matching capabilities with Fortrea’s global clinical development expertise, we can help international sponsors identify relevant patient populations, plan trials more effectively and support targeted recruitment.”

Fortrea’s oncology expertise is underpinned by thousands of operational professionals and supported by more than 50 oncology physicians on staff. This collaboration comes at a time when modern oncology drug development has accelerated the focus on precision medicine, biomarker-driven development and targeted patient identification. Working together, Fortrea and Omico can offer more efficient site selection and the ability to match patients with appropriate studies tied to their unique genomic data, enabling more people to participate in studies tailored to their specific condition in Australia.

About FortreaFortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn and X and Bluesky.

About OmicoOmico is an independent, national, not-for-profit research organisation changing the way we fight cancer. We work to improve outcomes for Australians with cancer by providing equitable access to precision oncology and translating scientific advances into clinical care and research, and generating the evidence needed to inform health policy and system reform. Working with Australia's leading cancer institutes, researchers, clinicians, industry partners, advocacy groups and government, we are accelerating molecular profiling, biomarker-led clinical trials, personalised cancer risk management and real-world evidence.

About PrOSPeCT PrOSPeCT is Australia's largest precision oncology initiative. Delivered by Omico and a national network of healthcare, research and industry partners, it provides eligible Australians with access to molecular profiling and matching to biomarker-led clinical trials and therapies (at no cost to the patient), while generating clinical, genomic, treatment and outcomes data to advance research, improve cancer care and inform future health policy.

**Fortrea Contacts:**Galen Wilson (Media) – 703-298-0802, [email protected] Kate Dillon (Media) – 646-818-9115, [email protected] Tracy Krumme (Investors) – 984-385-6707, [email protected]

Omico Contact: Kym Bramich (Communications) – +61 414 795 087, [email protected]

Fortrea Logo

Opt-Out Request Honored

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer. For more information, please see our Website Privacy Policy.

Allow All Cookies

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Cookies Details

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Cookies Details

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Cookies Details

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookies Details

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All Non-Essential Cookies

Powered by Onetrust

Prompts

Fortrea Holdings Inc. (ticker FTRE), listed in United States.

Company History

Date Change Detail
Mar 13, 2023 Renamed Silver Spinco Inc. → FORTREA HOLDINGS INC.

ETFs Holding Fortrea Holdings Inc.

ETF Weight in ETF Shares Market value As of
BSMC 1.74% 166,451 $ 2.896M Jun 30, 2026
MMSC 0.32% 8,063 $ 159.567K Nov 16, 2026
JMEE 0.21% 301,580 $ 5.908M Nov 17, 2026
AVSC 0.11% 170,972 $ 3.384M Nov 16, 2026
FSML 0.09% 6,730 $ 117.102K Jun 30, 2026
VFMF 0.08% 41,554 $ 763.347K Aug 31, 2026
RESM 0.08% 161 $ 2,801.40 Jun 30, 2026
VFMO 0.07% 72,482 $ 1.331M Aug 31, 2026
SMDX 0.06% 3,774 $ 74.687K Nov 17, 2026
DFAS 0.04% 615,311 $ 12.343M Nov 12, 2026
DFAT 0.02% 290,670 $ 5.831M Nov 12, 2026
DXUV 0.01% 41,653 $ 835.559K Nov 12, 2026
DFSU 0.01% 11,176 $ 224.191K Nov 12, 2026
DFAC 0.01% 331,281 $ 6.645M Nov 12, 2026
DCOR 0.01% 119,302 $ 2.393M Nov 12, 2026
DFAU 0.00% 26,800 $ 537.608K Nov 12, 2026
ACVF 0.00% 228 $ 4,370.76 Jul 31, 2026
DFUS 0.00% 29,154 $ 584.829K Nov 12, 2026
EBI 0.00% 8 $ 146.96 Aug 31, 2026
DFUV 0.00% 36 $ 722.16 Nov 12, 2026
AVUS 0.00% 1,280 $ 25.331K Nov 16, 2026